Ouro Medicines key facts
as of Oct 2026- Developer of innovative therapeutics designed to treat immune-mediated diseases by targeting underlying immune system dysfunction.
- Ouro Medicines is valued at approximately $1.7B as of Oct 2026 (last reported valuation).
- It has raised $120.0M; the latest was Merger/Acquisition ($1.7B) in Mar 2026.
- Notable investors include New Enterprise Associates, Norwest, Boyu Capital, UPMC Enterprises, Boai Wanwu (Shanghai) Venture Capital Management — 9 tracked in total.
- Status: Privately Held (backing).
Ouro Medicines's last reported valuation, Mar 2026. Nothing priced has surfaced since.
- ·Watch Ouro Medicines: the Monday email on marks, rounds and moves
Ouro Medicines funding rounds
No funding rounds for Ouro Medicines are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Ouro Medicines valuation
Ouro Medicines's last reported valuation was $1.7 billion in Mar 2026. No priced round, secondary trade or fund mark has surfaced since.
Ouro Medicines investors
9 investors are on record for Ouro Medicines, including New Enterprise Associates, Norwest, Boyu Capital and UPMC Enterprises.
About Ouro Medicines
Developer of innovative therapeutics designed to treat immune-mediated diseases by targeting underlying immune system dysfunction. The company offers a research-driven pipeline, advanced scientific capabilities in immune modulation, integrated discovery and development processes, and a focused approach to creating targeted therapies with validated outcomes, enabling patients with immune-mediated conditions to receive more precise and effective treatment options.
- Sector
- Healthcare
- HQ
- South San Francisco, CA, United States
- Founded
- 2024
- Employees
- 25
- Website
- ouromedicines.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.